Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that ...

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

For many years, mCRPC was considered to confer a terminal prognosis, with a median survival of 12 months from development of castrate resistance. [2] However, the advent of several new agents has ...

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

The median overall survival was 19.6 months with pembrolizumab plus docetaxel and 19.0 months with docetaxel alone. The combination of pembrolizumab and docetaxel does not improve outcomes over ...

Prostate Cancer Risk Increases By 45% Among Men Who Share One Troubling Behavior The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic ...